Circular RNA vaccines against SARS-CoV-2 and emerging variants
Liang Qu(Peking University), Zongyi Yi(Peking University), Yong Shen(Peking University), Liangru Lin(Peking University), Feng Chen(Peking University), Yiyuan Xu(Peking University), Zeguang Wu(Peking University), Huixian Tang(Peking University), Xiaoxue Zhang(Peking University), Feng Tian(Peking University), Chunhui Wang(Peking University), Xia Xiao(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaojing Dong(Chinese Academy of Medical Sciences & Peking Union Medical College), Li Guo(Chinese Academy of Medical Sciences & Peking Union Medical College), Shuaiyao Lu(Kunming Institute of Zoology), Chengyun Yang(Kunming Institute of Zoology), Cong Tang(Kunming Institute of Zoology), Yun Yang(Kunming Institute of Zoology), Wenhai Yu(Kunming Institute of Zoology), Junbin Wang(Kunming Institute of Zoology), Yanan Zhou(Kunming Institute of Zoology), Qing Huang(Kunming Institute of Zoology), Ayijiang Yisimayi(Peking University), Shuo Liu(National Institutes for Food and Drug Control), Weijin Huang(National Institutes for Food and Drug Control), Yunlong Cao(Peking University), Youchun Wang(National Institutes for Food and Drug Control), Zhuo Zhou(Peking University), Xiaozhong Peng(Kunming Institute of Zoology), Jianwei Wang(Kunming Institute of Zoology), Xiaoliang Sunney Xie(Peking University), Wensheng Wei(Peking University)
Cited by 603Open Access
Abstract
vaccine protected against both Delta and Omicron or functioned as a booster after two doses of either native- or Delta-specific vaccination, making it a favorable choice against the current variants of concern (VOCs) of SARS-CoV-2.
Related Papers
No related papers found
Powered by citation graph analysis